Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression

Medicine (United States)

Volumn 95, Issue 45, 2016, Pages

  Xu, Xiao Min ^a,b   Zou, De Zhi ^a,b   Shen, Liu Yan ^c   Liu, Yang ^a,b   Zhou, Xin Yu ^a,b   Pu, Jun Cai ^a,b   Dong, Mei Xue ^a,b   Wei, You Dong ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING KEY LABORATORY OF NEUROBIOLOGY   (China)

^c Luzhou People's Hospital   (China)

Author keywords

Antidepressants; Meta analysis; Post stroke depression

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDEPRESSANT AGENT; ASPARTATE AMINOTRANSFERASE; PLACEBO;

ARTICLE; DAILY LIFE ACTIVITY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; POST STROKE DEPRESSION; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; RATING SCALE; SENSITIVITY ANALYSIS; SIDE EFFECT; TREATMENT RESPONSE; CEREBROVASCULAR ACCIDENT; COMPLICATION; FEASIBILITY STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ANTIDEPRESSIVE AGENTS; DEPRESSION; FEASIBILITY STUDIES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME;

EID: 84996486499     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005349     Document Type: Article

References (29)

1. Hackett ML, Yapa C, Parag V, et al. Frequency of depression after stroke: A systematic review of observational studies. Stroke 2005;36:1330-40.
2. Feng C, FangM, Liu XY. The neurobiological pathogenesis of poststroke depression. Scientific World J 2014;2014:521349.
3. Gaete JM, Bogousslavsky J. Post-stroke depression. Expert Rev Neurother 2008;8:75-92.
4. Esparrago Llorca G, Castilla-Guerra L, Fernandez Moreno MC, et al. Post-stroke depression: An update. Neurologia 2015;30:23-31.
5. Angelelli P, Paolucci S, Bivona U, et al. Development of neuropsychiatric symptoms in poststroke patients: A cross-sectional study. Acta Psychiatr Scand 2004;110:55-63.
6. Pohjasvaara T, Vataja R, Leppävuori A, et al. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol 2001;8:315-9.
7. Cole MG, Elie LM, McCusker J, et al. Feasibility and effectiveness of treatments for post-stroke depression in elderly inpatients: systematic review. J Geriatr Psychiatry Neurol 2001;14:37-41.
8. Hackett ML, Anderson CS, House AO. Management of depression after stroke: A systematic review of pharmacological therapies. Stroke 2005;36:1098-103.
9. Chen Y, Guo JJ, Zhan S, et al. Treatment effects of antidepressants in patients with post-stroke depression: Ameta-analysis. Ann Pharmacother 2006;40:2115-22.
10. Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2008;4: CD003437DOI: 10. 1002/14651858. CD003437. pub3.
11. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Maryland State Med J 1965;14:61-5.
12. Ottenbacher KJ,Mann WC, Granger CV, et al. Inter-rater agreement and stability of functional assessment in the community-based elderly. Arch Phys Med Rehabil 1994;75:1297-301.
13. Aberg E, Adielsson G, Almqvist A. Multicenter trial of hemodilution in ischemic stroke-background and study protocol. Scandinavian Stroke Study Group. Stroke 1985;16:885-90.
14. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0 [updated March 2011]. London, UK:The Cochrane Collaboration; 2011.
15. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
16. Ponzio F, Marini G, Riva E. The efficacy of paroxetine in some kinds of "critical" patients. European Neuropsychopharmacology 2001;11 Suppl 2:S49-S50 Abstract P. 1. 29.
17. Chen W, Wang G-F, Chen X-H, et al. Effects of paroxetine on function recovery in patients with poststroke depression. Chinese J Clin Rehabil 2002;6:2014-5.
18. Lipsey JR, Robinson RG, Pearlson GD, et al. Nortriptyline treatment of post-stroke depression: A double-blind study. Lancet 1984;1: 297-300.
19. Reding MJ, Orto LA, Winter SW, et al. Antidepressant therapy after stroke. A double-blind trial. Arch Neurol 1986;43:763-5.
20. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099-104.
21. Raffaele R, Rampello L, Vecchio I, et al. Trazodone therapy of the poststroke depression. Arch Gerontol Geriatr 1996;22(suppl 1):217-20.
22. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: A placebo-controlled, double-blind study. Am J Psychiatry 2000;157:351-9.
23. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: A double-blind placebo-controlled study. Stroke 2000;31: 1829-32.
24. Fruehwald S, Gatterbauer E, Rehak P, et al. Early fluoxetine treatment of post-stroke depression-a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003;250: 347-51.
25. Murray V, von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005;66:708-16.
26. Rampello L, Alvano A, Chiechio S, et al. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study. Arch Gerontol Geriatr 2005;40:275-85.
27. Baer L, Ahern DK. Statistical problems with small sample size. Am J Psychiatry 1993;150:356-7.
28. Wickenberg-Bolin U, Goransson H, Fryknas M, et al. Improved variance estimation of classification performance via reduction of bias caused by small sample size. BMC Bioinformatics 2006;7:127.
29. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 2000;132: 738-42.